Blood Cancers | Tumor

Blood Cancer Drug Decreases Levels of Anti-Fungal Medication

March 19th 2024, 9:00pm

Article

Patients taking Tibsovo to treat MDS or AML may want to discuss the appropriate medications to treat and prevent infections, an expert said.

FDA Committee in Favor of Imetelstat for Transfusion-Dependent MDS

March 15th 2024, 7:00pm

Article

The Oncologic Drug Advisory Committee voted that the benefits of imetelstat outweigh the risks for transfusion-dependent myelodysplastic syndrome and anemia.

Follow-Ups Help Prevent ‘Dangerous’ Outcomes in Blood Cancer Survivors

March 8th 2024, 8:00pm

Article

Attending follow-up appointments as blood cancer survivors can help prevent more dangerous outcomes, including secondary cancers, an expert told CURE®.

Frailty Can Lengthen Post-Transplant Hospital Stays

March 1st 2024, 2:00pm

Video

Consulting physical therapy early on and speaking up to the health care team can help patients with blood cancer be more prepared for a hematopoietic stem cell transplant, an expert said.

FDA Approves Easier-to-Swallow Imbruvica Formulation

February 29th 2024, 10:00pm

Article

An oral suspension formula of Imbruvica received the green light from the Food and Drug Administration to be used in all approved indications.

Trial Evaluates Reduced Chemo Post-Stem Cell Transplant in Blood Cancers

February 26th 2024, 10:00pm

Article

The first patient has been enrolled in a clinical trial evaluating a reduced dose of post-transplant immunosuppressive chemotherapy cyclophosphamide for patients with blood cancers.

Orca-T Improves Post-Transplant Survival in Patients With Blood Cancers

February 26th 2024, 4:00pm

Article

Orca-T outperformed post-transplant cyclophosphamide when it came to relapse-free survival and overall survival in patients with blood cancer who underwent a stem cell transplantation from a matched unrelated donor.

Obesity May Affect GVHD Risk After Stem Cell Transplant

February 25th 2024, 3:00pm

Video

Patients who were obese tended to have an increased risk of moderate to severe GVHD after undergoing allogeneic hematopoietic cell transplantation, research showed.

Drug Duo Is Efficacious in Treating Posttransplant GVHD

February 24th 2024, 3:00pm

Article

Jakafi plus Rezurock showed promise in treating graft-versus-host disease in patients who underwent undergone allogeneic hematopoietic cell transplantation.

New Drug May Decrease Need for Blood Draws in Patients With PV

February 23rd 2024, 10:00pm

Article

Treatment with rusfertide led to a decrease in the need for blood draws and decreased levels of red blood cells in patients with polycythemia vera.